In a group of 43 cancer patients, TF-mediated procoagulant activity (factor Xa generation) on EVs was higher in five patients who developed VTE within six months than in the non-VTE group [60], and in another group of 60 cancer patients without VTE at the time of enrolment, four patients developed thromboembolic disease within a year and all were positive for TF+EVs [55]. The gene discussed is F10; the disease is cancer.